Home   /   Pressrelease    /   

XPS sold to pediatric transpl...

XPS™ sold to pediatric transplantation clinic in Italy

A pediatric transplantation clinic in Rome, Italy, has purchased an XPS™. This is the first XPS ™ for a pediatric hospital which will enable more transplants for children and adolescents with terminal lung disease.

There are approximately 200 lung transplants performed every year in Italy, whereof today only a few are pediatric lung transplants. The most common indication for lung transplantation in children is Cystic Fibrosis, a genetic disorder that causes thick mucus in the lungs. Clinics in Italy have been among the first to use EVLP to increase the proportion of lungs for transplantation to adults.

According to the Company’s business model, the pricing strategy for capital goods, that is the EVLP machines LS™ and XPS™, is so designed that sales of capital goods do not have a significant financial impact on the Company. According to the Company’s pricing strategy, future sales of STEEN Solution™ for use in the EVLP machines and accompanying single-use items are of financial significance for the Company.  

 “The EVLP technology, which allows more donated lungs to be used, has so far been used solely to evaluate lungs for transplantation to adults. The fact that the pediatric clinic in Rome is now the first in the world to buy an XPS ™ is very gratifying as it opens up to be able to expand the use of donated lungs for transplantation for children with terminal lung diseases.”, says Magnus Nilsson,

CEO of XVIVO Perfusion.

March 31, 2020
Gothenburg
Magnus Nilsson, CEO

XVIVO Perfusion AB (publ)

Fill out the form to watch the video